Serum lipid profile due to risperidone treatment in child and youth patients

Karaman M. G., Yurteri N., Ozdemir E., Kala S., Ankarali H., Karaman F. E., ...More

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.12, no.4, pp.295-300, 2011 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 4
  • Publication Date: 2011
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.295-300
  • Erciyes University Affiliated: No


Objective: Atypical antipsychotics (AAPs) have been reported to cause metabolic dysregulation that may result in AAPs-related weight gain. The purpose of this study was to assess triglyceride, cholesterol and weight changes among risperidone-treated child and youths. Methods: Eighty subjects treated with risperidone for any psychiatric disturbances were included in the study. Fasting total low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, (HDL-C), total cholesterol (TC), and triglyceride (TG) levels were measured at baseline and at 12 months of treatment. Results: There was no significant difference between baseline mean levels of TG, TC, HDL-C and LDL-C and twelfth months mean levels of TG, TC, HDL-C and LDL-C (respectively p=0.341, p=0.135, p=0.414, p=0.411, p=0.707). Comparison of baseline and 12 months data with respect to the age groups were presented in table 2. There was no significant association with age, gender, risperidone dose and changes of serum TG, TC, LDL-C or HDL-C levels. Conclusion: In conclusion, this study did not identify significant associations between dyslipidemia and one year risperidone treatment in children and adolescents. Because little long-term lipid profile follow-up is available with atypical antipsychotics treatment in youths, controlled studies in larger samples should be carried out to reveal the frequency and the risk factors of dyslipidemia. (Anatolian Journal of Psychiatry 2011; 12:295-300)